GEN Pharmaceuticals Receives Ethical Approval for Phase II Parkinson's Disease Trial of Mitochondrial-Targeting Drug SUL-238
核心洞察
GEN Pharmaceuticals (搜索) has received ethical approval from the BEBO Foundation (搜索) in the Netherlands to initiate a Phase II clinical trial of SUL-238, a novel hibernation-inspired drug targeting mitochondrial dysfunction in Parkinson's disease (搜索) patients.
The SHEPHERD study is a randomized, double-blind, placebo-controlled trial that will assess SUL-238's effects on high-energy phosphates using magnetic resonance spectroscopy in early-stage, untreated Parkinson's disease (搜索) patients.
Patient enrollment is scheduled to begin in April 2026 at a clinical site in Groningen, Netherlands, with participants receiving either SUL-238 or placebo daily over a 28-day treatment period.
GEN Pharmaceuticals (搜索) has received ethical approval from the BEBO Foundation (搜索) for the Assessment of Ethics of Biomedical Research in the Netherlands to proceed with a Phase II clinical trial of SUL-238, a novel drug candidate targeting mitochondrial dysfunction in patients with Parkinson's disease (搜索). The approval enables the Turkish specialty pharmaceutical company to activate its clinical site in Groningen and begin patient enrollment in April 2026.
Phase II SHEPHERD Trial Design
The Phase II proof-of-concept study, formally titled "A Phase 2, Randomized, Double-blind, Placebo-Controlled, Single-Center Study to Assess the effects of SUL-238 on High Energy Phosphates with Magnetic Resonance Spectroscopy (31P-MRS) in patients with Early, untreated Parkinson's Disease (搜索)," will evaluate the drug's mechanism of action in early-stage patients.
The SHEPHERD study will assess SUL-238's effects on high-energy phosphates using magnetic resonance spectroscopy (31P-MRS) in patients diagnosed with early-stage, untreated Parkinson's disease (搜索). Participants will receive either SUL-238 or placebo daily over a 28-day treatment period, with clinic visits scheduled every two weeks for routine check-ups and testing during treatment, followed by an additional assessment 28 days after the final dose.
Each participant will maintain a symptom diary and record their oral intake of SUL-238 throughout the study period. The primary aim focuses on evaluating how SUL-238 works through MRS scans, which function similarly to magnetic resonance imaging (MRI) scans, while also examining the drug's safety profile.
Targeting Mitochondrial Dysfunction in Neurodegeneration
SUL-238 represents a first-in-class, hibernation-inspired small molecule designed to target mitochondria (搜索), often referred to as the 'powerhouse' of the cell. The compound supports mitochondrial bioenergetics via complex I/IV (搜索) activation and enhances mitochondrial function across various preclinical models for neurodegenerative, cardiovascular, and renal diseases, as well as in accelerated aging models.
Mitochondrial dysfunction and oxidative damage are implicated in the pathophysiology of neurodegenerative disorders (搜索), including Parkinson's disease (搜索) and Alzheimer's disease (搜索). Since mitochondria (搜索) are highly multifunctional organelles, their integrity is essential for neuronal function and survival.
Drug Development and Safety Profile
SUL-238 exhibits a favorable pharmacokinetic profile and demonstrates high cerebrospinal fluid penetration, critical characteristics for treating central nervous system disorders. The compound has undergone extensive safety evaluation in both preclinical studies and clinical Phase I trials.
GEN Pharmaceuticals (搜索) licenses SUL-238 from Sulfateq B.V. (搜索), a Dutch biotech company based in Groningen, specifically for neurodegenerative disease applications. Sulfateq has developed a novel class of small-molecule SUL compounds designed to maintain mitochondrial health.
Addressing Unmet Medical Need
Parkinson's disease (搜索) represents the most common neurodegenerative movement disorder, affecting up to 2% of individuals aged above 60 years. The disease follows a progressive course, and currently no proven strategies exist for slowing the progression of Parkinson's disease.
"Following the ethical approval, we look forward to starting patient enrollment in the Netherlands. This Phase II trial will be another key milestone toward addressing neurodegenerative diseases at its biological foundation," stated Abidin Gülmüş, Chairman of GEN Pharmaceuticals (搜索).
The trial represents a significant step in GEN's commitment to developing innovative therapies across multiple therapeutic areas through substantial R&D investments and global collaborations. Founded in 1998, GEN operates as Turkey's leading specialty pharmaceutical company, developing and manufacturing products at its GMP-certified production facility while pursuing original drug development through two dedicated R&D centers.